Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 Jul 4

PMID 26138001

Citations 11

Authors

Arunas Vaitkevicius

Gintaras Kaubrys

Egle Audronyte

Affiliations

Soon will be listed here.

Abstract

Background: Latency of P300 subcomponent of event-related potentials (ERPs) increases in Alzheimer disease (AD) patients, which correlate well with cognitive impairment. Cholinesterase inhibitors (ChEIs) reduce P300 latency in AD patients with parallel improvement in cognition. It is not known whether N200 response to ChEIs is similar to that of P300. The aim of this study was to evaluate and compare characteristics of P300 and N200 in AD patients, treatment-naïve and on stable donepezil treatment, matched by age, education, sex, and cognitive function.

Material And Methods: We recruited 22 consecutive treatment-naïve AD patients (AD-N group), 22 AD patients treated with a stable donepezil dose of 10 mg/day for at least 3 months (AD-T group), and 50 healthy controls were recruited. Neuropsychological testing (MMSE, ADAS-Cog, and additional tests) and ERP recording was performed and analyzed.

Results: All groups did not differ according to age, duration of education, or sex (p>0.05). AD-N and AD-T groups did not differ according to cognitive function. The AD-T group had longer duration of disease than the AD-N group (p<0.001). The AD-T and AD-N groups did not differ in P300 latencies (p=0.49). N200 latency was longer in the AD-T group (p<0.001). The general linear model showed that significant predictors of P300 latency were age (p=0.019) and AD treatment status (p<0.001). Duration of AD was a significant predictor of N200 latency (p=0.004).

Conclusions: The response of N200 latency to donepezil treatment differs from the response of P300. P300 is a better marker of ChEI treatment-dependent cognitive functions. N200 is more dependent on the duration of AD.

Citing Articles

Evaluation of Event-Related Potentials in Somatic Diseases - Systematic Review.

Popiolek A, Niznikiewicz M, Borkowska A, Bielinski M Appl Psychophysiol Biofeedback. 2024; 49(3):331-346.

PMID: 38564137 DOI: 10.1007/s10484-024-09642-5.

Response of Circulating Inflammatory Markers to Intermittent Hypoxia-Hyperoxia Training in Healthy Elderly People and Patients with Mild Cognitive Impairment.

Serebrovska Z, Xi L, Tumanovska L, Shysh A, Goncharov S, Khetsuriani M Life (Basel). 2022; 12(3).

PMID: 35330183 PMC: 8953753. DOI: 10.3390/life12030432.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.

Hua X, Church K, Walker W, LHostis P, Viardot G, Danjou P J Alzheimers Dis. 2022; 86(3):1399-1413.

PMID: 35180125 PMC: 9108585. DOI: 10.3233/JAD-215511.

Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Event-Related Potential Studies.

Tarawneh H, Mulders W, Sohrabi H, Martins R, Jayakody D J Alzheimers Dis. 2021; 84(1):419-448.

PMID: 34569950 PMC: 8609695. DOI: 10.3233/JAD-210556.

Single-Trial Mechanisms Underlying Changes in Averaged P300 ERP Amplitude and Latency in Military Service Members After Combat Deployment.

Trongnetrpunya A, Rapp P, Wang C, Darmon D, Costanzo M, Nathan D Front Hum Neurosci. 2019; 13:377.

PMID: 31708761 PMC: 6824216. DOI: 10.3389/fnhum.2019.00377.

References

Katada E, Sato K, Ojika K, Ueda R . Cognitive event-related potentials: useful clinical information in Alzheimer's disease. Curr Alzheimer Res. 2005; 1(1):63-9. DOI: 10.2174/1567205043480609. View

Bennys K, Portet F, Touchon J, Rondouin G . Diagnostic value of event-related evoked potentials N200 and P300 subcomponents in early diagnosis of Alzheimer's disease and mild cognitive impairment. J Clin Neurophysiol. 2007; 24(5):405-12. DOI: 10.1097/WNP.0b013e31815068d5. View

Ritter W, Simson R, Vaughan Jr H, Macht M . Manipulation of event-related potential manifestations of information processing stages. Science. 1982; 218(4575):909-11. DOI: 10.1126/science.7134983. View

Dierks T, Frolich L, Ihl R, Maurer K . Event-related potentials and psychopharmacology. Cholinergic modulation of P300. Pharmacopsychiatry. 1994; 27(2):72-4. DOI: 10.1055/s-2007-1014282. View

Frodl T, Hampel H, Juckel G, Burger K, Padberg F, Engel R . Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology. 2002; 39(2):175-81. DOI: 10.1017/S0048577202010260. View

Papaliagkas V, Kimiskidis V, Tsolaki M, Anogianakis G . Cognitive event-related potentials: longitudinal changes in mild cognitive impairment. Clin Neurophysiol. 2011; 122(7):1322-6. DOI: 10.1016/j.clinph.2010.12.036. View

Werber E, Gandelman-Marton R, Klein C, Rabey J . The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. J Neural Transm (Vienna). 2003; 110(6):659-69. DOI: 10.1007/s00702-003-0817-9. View

Lee M, Lee S, Moon E, Moon Y, Kim S, Kim S . Neuropsychological correlates of the P300 in patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 40:62-9. DOI: 10.1016/j.pnpbp.2012.08.009. View

Sosa-Ortiz A, Acosta-Castillo I, Prince M . Epidemiology of dementias and Alzheimer's disease. Arch Med Res. 2012; 43(8):600-8. DOI: 10.1016/j.arcmed.2012.11.003. View

10.

Thomas A, Iacono D, Bonanni L, DAndreamatteo G, Onofrj M . Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin Neuropharmacol. 2001; 24(1):31-42. DOI: 10.1097/00002826-200101000-00007. View

11.

Lai C, Lin R, Liou L, Liu C . The role of event-related potentials in cognitive decline in Alzheimer's disease. Clin Neurophysiol. 2009; 121(2):194-9. DOI: 10.1016/j.clinph.2009.11.001. View

12.

Juckel G, Clotz F, Frodl T, Kawohl W, Hampel H, Pogarell O . Diagnostic usefulness of cognitive auditory event-related p300 subcomponents in patients with Alzheimers disease?. J Clin Neurophysiol. 2008; 25(3):147-52. DOI: 10.1097/WNP.0b013e3181727c95. View

13.

Chang Y, Chen H, Hsu C, Tang S, Liu C . Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study. J Clin Neurophysiol. 2014; 31(1):81-5. DOI: 10.1097/01.wnp.0000436899.48243.5e. View

14.

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi H . Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2009; 3(3):186-91. DOI: 10.1016/j.jalz.2007.04.381. View

15.

Katada E, Sato K, Sawaki A, Dohi Y, Ueda R, Ojika K . Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol. 2003; 16(1):39-43. DOI: 10.1177/0891988702250561. View

16.

Gironell A, Garcia-Sanchez C, Estevez-Gonzalez A, Boltes A, Kulisevsky J . Usefulness of p300 in subjective memory complaints: a prospective study. J Clin Neurophysiol. 2005; 22(4):279-84. DOI: 10.1097/01.wnp.0000173559.60113.ab. View

17.

Howe A . Meta-analysis of the endogenous N200 latency event-related potential subcomponent in patients with Alzheimer's disease and mild cognitive impairment. Clin Neurophysiol. 2013; 125(6):1145-51. DOI: 10.1016/j.clinph.2013.10.019. View

18.

. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012; 8(2):131-68. DOI: 10.1016/j.jalz.2012.02.001. View

19.

Cummings J, Banks S, Gary R, Kinney J, Lombardo J, Walsh R . Alzheimer's disease drug development: translational neuroscience strategies. CNS Spectr. 2013; 18(3):128-38. DOI: 10.1017/S1092852913000023. View

20.

Paci C, Gobbato R, Carboni T, Sanguigni S, Santone A, Curatola L . P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia. Neurol Sci. 2006; 26(6):435-7. DOI: 10.1007/s10072-006-0528-8. View